As of Apr 20
| +0.10 / +0.58%|
The 4 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 34.50, with a high estimate of 41.00 and a low estimate of 19.00. The median estimate represents a +99.42% increase from the last price of 17.30.
The current consensus among 5 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.